✦ LIBER ✦

Teratogenic phthalate esters and metabolites activate the nuclear receptors PPARs and induce differentiation of F9 cells

✍ Scribed by Alfonso Lampen; Susan Zimnik; Heinz Nau

Book ID: 114087018
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 473 KB
Volume: 188
Category: Article
ISSN: 0041-008X
DOI: 10.1016/s0041-008x(03)00014-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bioassay for the Identification of Natur

Bioassay for the Identification of Natural Product-Based Activators of Peroxisome Proliferator-Activated Receptor-γ (PPARγ): The Marine Sponge Metabolite Psammaplin A Activates PPARγ and Induces Apoptosis in Human Breast Tumor Cells

✍ Mora, Flor D.; Jones, Deborah K.; Desai, Prashant V.; Patny, Akshay; Avery, Mitc 📂 Article 📅 2006 🏛 American Chemical Society 🌐 English ⚖ 405 KB

Distinct roles of the co-activators p300

Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation

✍ Yokoyama, Kazunari K.; Kawasaki, Hiroaki; Eckner, Richard; Yao, Tso-Pang; Taira, 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 477 KB

Analysis of the DNA-binding activities o

Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells

✍ Larsson, Lars-Gunnar; Bahram, Fuad; Burkhardt, Hannelore; Lüscher, Bernhard 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 968 KB

Resistance to 1,25D-induced differentiat

Resistance to 1,25D-induced differentiation in human acute myeloid leukemia HL60-40AF cells is associated with reduced transcriptional activity and nuclear localization of the vitamin D receptor

✍ Edward Garay; Robert Donnelly; Xuening Wang; George P. Studzinski 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

## Abstract The anti‐neoplastic effects of 1,25‐dihydroxyvitamin D~3~ (1,25D) are well documented in numerous tumor cell systems and animal models of cancer. However, despite this pre‐clinical success, the clinical use of 1,25D is currently impeded by the dose‐limiting hypercalcemia, and the risk o